Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GFH375 plus cetuximab versus investigator's choice in previously treated KRAS G12D-mutant metastatic colorectal cancer
CTR20263921Phase 3Active
- Sponsor
- GenFleet Therapeutics
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of GFH375, cetuximab in colorectal cancer (CRC), metastatic colorectal adenocarcinoma (mCRC), sponsored by GenFleet Therapeutics. Started Oct 2026; status: active.
02
Drugs
GFH375cetuximab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on CTR20263921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263921.